MEDI3617, a human anti-Angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models

International Journal of Oncology

Volumn 40, Issue 5, 2012, Pages 1321-1330

  Leow, Ching Ching ^a   Coffman, Karen ^a   Inigo, Ivan ^a   Breen, Shannon ^a   Czapiga, Meggan ^b   Soukharev, Serguei ^b   Gingles, Neill ^c   Peterson, Norman ^b   Fazenbaker, Christine ^a   Woods, Rob ^b   Jallal, Bahija ^a,b   Ricketts, Sally Ann ^c   Lavallee, Theresa ^b   Coats, Steve ^a   Chang, Yong ^a  

^a MEDIMMUNE   (United States)

^b AstraZeneca ^*  (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Ang2; Angiogenesis; Hypoxia; Xenograft

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 2; MEDI 3617; PACLITAXEL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CORROSION CASTING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCENCE; HEK293 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL; PHOSPHORYLATION; RECEPTOR, TIE-2; RETINAL NEOVASCULARIZATION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859488747     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1366     Document Type: Article

References (45)

1. Augustin HG, Koh GY, Thurston G and Alitalo K: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10: 165-177, 2009.
2. Maisonpierre PC, Suri C, Jones PF, et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997. (Pubitemid 27450643)
3. Asahara T, Chen D, Takahashi T, et al: Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 83: 233-240, 1998. (Pubitemid 28371312)
4. Inoue M, Hager JH, Ferrara N, Gerber HP and Hanahan D: VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1: 193-202, 2002. (Pubitemid 41039165)
5. Hanahan D: Signaling vascular morphogenesis and maintenance. Science 277: 48-50, 1997.
6. Fiedler U, Scharpfenecker M, Koidl S, et al: The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103: 4150-4156, 2004. (Pubitemid 38685356)
7. Koga K, Todaka T, Morioka M, et al: Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61: 6248-6254, 2001. (Pubitemid 32762564)
8. Geva E, Ginzinger DG, Zaloudek CJ, Moore DH, Byrne A and Jaffe RB: Human placental vascular development: vasculogenic and angiogenic (branching and nonbranching) transformation is regulated by vascular endothelial growth factor-A, angiopoietin-1, and angiopoietin-2. J Clin Endocrinol Metab 87: 4213-4224, 2002.
9. Hackett SF, Wiegand S, Yancopoulos G and Campochiaro PA: Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol 192: 182-187, 2002. (Pubitemid 34747786)
10. Mandriota SJ and Pepper MS: Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 83: 852-859, 1998. (Pubitemid 28489082)
11. Vajkoczy P, Farhadi M, Gaumann A, et al: Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 109: 777-785, 2002. (Pubitemid 34263154)
12. Ahmad SA, Liu W, Jung YD, et al: Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer 92: 1138-1143, 2001. (Pubitemid 32861662)
13. Shim WS, Ho IA and Wong PE: Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res 5: 655-665, 2007. (Pubitemid 47105484)
14. Tait CR and Jones PF: Angiopoietins in tumours: the angiogenic switch. J Pathol 204: 1-10, 2004. (Pubitemid 39214476)
15. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K and Wands JR: Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 103: 341-345, 1999. (Pubitemid 29069983)
16. Anargyrou K, Terpos E, Vassilakopoulos TP, et al: Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 93: 451-454, 2008. (Pubitemid 351398649)
17. Caine GJ, Lip G, Zanetto U, Maheshwari M, Stonelake PS and Blann AD: A comparison of plasma versus histologic indices of angiogenic markers in breast cancer. Appl Immunohistochem Mol Morphol 15: 382-388, 2007. (Pubitemid 350307842)
18. Sie M, Wagemakers M, Molema G, Mooij JJ, de Bont ES and den Dunnen WF: The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neurosurg 110: 147-155, 2009.
19. Brown JL, Cao ZA, Pinzon-Ortiz M, et al: A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 9: 145-156, 2010.
20. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J and Breitman ML: Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7: 1471-1480, 1992.
21. Helfrich I, Edler L, Sucker A, et al: Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 15: 1384-1392, 2009.
22. Sato TN, Tozawa Y, Deutsch U, et al: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376: 70-74, 1995.
23. De Palma M, Venneri MA, Galli R, et al: Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8: 211-226, 2005. (Pubitemid 41317592)
24. Gale NW, Thurston G, Hackett SF, et al: Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 3: 411-423, 2002.
25. Liang WC, Wu X, Peale RV, et al: Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281: 951-961, 2006.
26. Thomas M and Augustin HG: The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12: 125-137, 2009.
27. Park JH, Park KJ, Kim YS, et al: Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132: 200-206, 2007.
28. Huang H, Bhat A, Woodnutt G and Lappe R: Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 10: 575-585, 2010.
29. Nasarre P, Thomas M, Kruse K, et al: Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 69: 1324-1333, 2009.
30. Mazzieri R, Pucci F, Moi D, et al: Targeting Ang2/Tie2 axis inhibits tumor growth and metastasis by impairing angiogensis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19: 512-526, 2011.
31. Bergers G, Brekken R, McMahon G, et al: Matrix mettaloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744, 2000.
32. Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603, 2008.
33. Paez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumor and increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.
34. Herbst RS, Hong D, Chap L, et al: Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27: 3557-3565, 2009.
35. Rosen L, Mendelson D, Cohen R, et al: First-in-human dose-escalation safety and PK trial of a novel intravenous humanized monoclonal CovX body inhibiting angiopoietin 2. J Clin Oncol 28 (Suppl 15): 2524, 2010.
36. Falcon BL, Hashizume H, Koumoutsakos P, et al: Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 175: 2159-2170, 2009.
37. Hashizume H, Falcon BL, Kuroda T, et al: Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 70: 2213-2223, 2010.
38. Bagri A, Berry L, Gunter B, et al: Effects of Anti-VEGF treatment duration on tumor growth, tumor regrowth and treatment efficacy. Clin Cancer Res 16: 3887-3900, 2010.
39. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239, 2009.
40. Holopainen T, Saharinen P, D'Amico, et al: Angiopoietin-2 blocking antibody acts at endothelial cell-cell junctions and inhibits lung metastasis. J Natl Cancer Inst: doi: 10.1093/jnci/djs009.
41. Imanishi Y, Hu B, Jarzynka MJ, et al: Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrin-mediated pathway. Cancer Res 67: 4254-4263, 2007. (Pubitemid 46815072)
42. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
43. Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40, 2006. (Pubitemid 43108832)
44. Chae SS, Kamoun WS, Farrar CT, et al: Angiopoietin-2 interferes with anti-VEGFR2- induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16: 3618-3627, 2010.
45. Koh YJ, Kim HZ, Hwang SI, et al: Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis and vascular leakage. Cancer Cell 18: 171-184, 2010.